Sign in Subscribe

This post is for paying subscribers only

Already have an account? Sign in.

CERo Therapeutics: AML Drug Gains FDA Fast Track

CERo's AML drug, CER-1236, received FDA Fast Track & Orphan Drug status and is in a Phase 1/1b trial. CERo Therapeutics faces a Nasdaq delisting challenge due to low stockholders' equity, but has appealed and plans to raise funds.